Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of “Hold” by Brokerages

Posted by Stanley Muller on Aug 24th, 2026

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) have received a consensus rating of “Hold” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $7.50.

CRDF has been the subject of several analyst reports. Craig Hallum cut Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a report on Wednesday, June 3rd. TD Cowen cut Cardiff Oncology from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. William Blair downgraded Cardiff Oncology from an “outperform” rating to a “market perform” rating in a report on Tuesday, August 11th. Wall Street Zen lowered Cardiff Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright cut shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st.

Get Our Latest Analysis on CRDF

Insider Activity at Cardiff Oncology

In related news, CEO Mani Mohindru purchased 24,703 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were purchased at an average cost of $1.21 per share, with a total value of $29,890.63. Following the purchase, the chief executive officer owned 24,703 shares of the company’s stock, valued at $29,890.63. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gary W. Pace bought 30,000 shares of the firm’s stock in a transaction dated Thursday, June 18th. The stock was purchased at an average price of $1.22 per share, for a total transaction of $36,600.00. Following the transaction, the director owned 1,356,376 shares of the company’s stock, valued at approximately $1,654,778.72. This represents a 2.26% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 8.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cardiff Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Hsbc Holdings PLC acquired a new stake in Cardiff Oncology in the 2nd quarter valued at about $37,000. Glenview Trust Co purchased a new position in Cardiff Oncology in the 2nd quarter worth approximately $56,000. Capstone Investment Advisors LLC acquired a new position in shares of Cardiff Oncology during the 2nd quarter worth approximately $67,000. X Square Capital LLC purchased a new stake in shares of Cardiff Oncology in the second quarter valued at approximately $267,000. Finally, Ieq Capital LLC purchased a new stake in shares of Cardiff Oncology in the second quarter valued at approximately $58,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Cardiff Oncology Stock Performance

NASDAQ CRDF traded up $0.14 on Monday, reaching $1.02. 667,034 shares of the company’s stock traded hands, compared to its average volume of 1,177,771. The firm has a market cap of $79.43 million, a price-to-earnings ratio of -1.70 and a beta of 1.49. The stock has a 50 day moving average price of $1.07 and a 200-day moving average price of $1.48. Cardiff Oncology has a fifty-two week low of $0.76 and a fifty-two week high of $3.31.

Cardiff Oncology (NASDAQ:CRDF – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.06 million. Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%. As a group, equities research analysts anticipate that Cardiff Oncology will post -0.63 EPS for the current fiscal year.

Cardiff Oncology Company Profile

(Get Free Report)

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.

Analyst Recommendations for Cardiff Oncology (NASDAQ:CRDF)

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.